Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + FOLFIRI in Metastatic Colorectal Cancer (VELOUR)
NCT00561470Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2007
- Primary completion
- Feb 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Aflibercept + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Overall Survival. Started Nov 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00561470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561470.